Welcome
Mergers & Antitrust Law News

Sun, Ranbaxy Lose Interlocutory Appeal Bid in Generic Delay Case

Feb. 18, 2020, 8:49 PM

Sun Pharmaceutical Industries Ltd. must wait to appeal a decision greenlighting claims that the company used regulatory gamesmanship to corner the market for three generic drugs, a Boston federal judge ruled, rejecting Sun’s bid to take the case back to the First Circuit.

“A second interlocutory appeal of the same issues in the same procedural posture” would “further delay” the “already prolonged litigation,” Judge Nathaniel M. Gorton wrote Feb. 14.

The multidistrict lawsuit alleges racketeering and violations of antitrust and consumer laws by Sun, the world’s largest specialty pharmacy, and its subsidiary Ranbaxy Inc.

It accuses them of submitting bogus...

To read the full article log in. To learn more about a subscription click here.